Elderly women with Parkinson's disease (PD) represent a specific patient population that may benefit from individualized treatment strategies. PD has been shown to occur approximately twice as often in men than in women, resulting in theories regarding estrogen being protective against the disease and as a potential treatment strategy. Given women's longer life expectancy they are more likely to reach an age where antiparkinsonian medications are associated with side-effects. This paper will review medical and surgical treatments as well as the relationship of gender and age with respect to the management of PD.
RoccaWA, BowerJH, MaraganoreDM, AhlskogJE, GrossardtBR, de AndradeM, MeltonLJIII. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology2007; [Epub ahead of print]
7.
CurrieLJ, Harrison My TrugmanJMPostmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol2004; 61: 886-8
8.
TsangKL, HoSL, LoSK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology2000; 54: 2292-8
9.
NicolettiA, ArabiaG, PugliesePHormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin Neuropharmacol2007; 30: 276-80
10.
ArabiaG, ZappiaM, BoscoDBody weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci2002; 23: S53-4
11.
The Women's Health Initiative Steering Committee.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomized control trial. JAMA2004; 291: 1701-12
12.
RossouwJE, AndersonGL, PrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002; 288: 321-33
13.
RossouwJE, PrenticeRL, MansonJEPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007; 297: 1465-77
